Catherine Sermet
Overview
Explore the profile of Catherine Sermet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe C, Ferrario A, et al.
Front Public Health
. 2018 Dec;
6:328.
PMID: 30568938
There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever...
2.
Vella Bonanno P, Ermisch M, Godman B, Martin A, Van Den Bergh J, Bezmelnitsyna L, et al.
Front Pharmacol
. 2017 Sep;
8:497.
PMID: 28878667
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines...
3.
Herr M, Sirven N, Grondin H, Pichetti S, Sermet C
Eur J Clin Pharmacol
. 2017 Jun;
73(9):1165-1172.
PMID: 28601963
Purpose: This study analyses the relationship between medication use and frailty by considering the quantity of medications prescribed (polypharmacy) and the quality of medication prescribing (according to French criteria for...
4.
Ermisch M, Bucsics A, Vella Bonanno P, Arickx F, Bybau A, Bochenek T, et al.
Front Pharmacol
. 2016 Oct;
7:305.
PMID: 27733828
Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope...
5.
Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al.
Pharmaceuticals (Basel)
. 2016 Oct;
3(8):2470-2494.
PMID: 27713363
Pharmaceutical expenditures in ambulatory care rose rapidly in Europe in the 1990s and early 2000s. This was typically faster than other components of healthcare spending, leading to reforms to moderate...
6.
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
de Bruijn W, Ibanez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, et al.
Front Pharmacol
. 2016 Aug;
7:197.
PMID: 27516740
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines...
7.
Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al.
Pharmacoeconomics
. 2015 Jun;
33(9):905-24.
PMID: 26048353
Pharmaceutical expenditure has increased rapidly across many Organisation for Economic Cooperation and Development (OECD) countries over the past three decades. This growth is an increasing concern for governments and other...
8.
Andrade L, Sermet C, Pichetti S
Eur J Health Econ
. 2014 Dec;
17(1):45-60.
PMID: 25501258
Pharmaceutical firms have been criticized for concentrating efforts of R&D on the so-called me-too or follow-on drugs. There have been many comments for and against the dissemination of these incremental...
9.
Godman B, Malmstrom R, Diogene E, Gray A, Jayathissa S, Timoney A, et al.
Expert Rev Clin Pharmacol
. 2014 Dec;
8(1):77-94.
PMID: 25487078
Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to...
10.
Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al.
Front Pharmacol
. 2014 Jul;
5:106.
PMID: 24987370
Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices....